[Effect of 2 therapeutic protocols in minor forms of respiratory allergy].
The purpose of this prospective study was to determine in 261 children whether the "minor" allergic respiratory diseases (MARD) (chronic cough, bronchitis asthmatic, rhinopharyngitis, recurrent otitis media, croup) are due to inhalants allergens and, if so, whether they can be treated with two therapeutic protocols. First protocol (B) included nonspecific immunotherapy with bacterial vaccines aerosols + Fusafungin sprays and Ketotifen were employed in 103 children; and the second protocol (C) included specific immunotherapy with D. Pteronyssinus, in 64 children. This two formula were compared with a control group (67 children). The children were previous tested by PRIST, prick test with house dust, mite, pollens, moulds and by RAST to house dust and mite allergens (56.5% positive results). The follow up study was conducted over 1 to 4 years periods (mean = 1.95 years). Each child's behaviour was monitored regularly by parents and doctor. 54 children drop out this study. Specific hyposensitized children (C) had significant higher improvement (83.6% - p less than 0.01) than B protocol (52.4%) and than control group (16.4%) in overall population. During this study, 51 children with previous MARD go on to more serious obstructive lung disease - asthma: 37.3% in the control group, 23.3% in B group and 6% in hyposensitized group. The results suggest that it is important in children with MARD to monitor the levels of the total and specific Ig E and cutaneous reactions with prick test to common allergens; specific immunotherapy is highly indicated in atopic MARD; in non-atopic MARD children, ketotifen and nonspecific immunotherapy have satisfactory results. Total and specific Ig E levels and prick test must be repeated once a year in this non-atopic children in order to find the specific allergens.
Rocha
E M
EM
D000293:Adolescent; D000336:Aerosols / Q000627:therapeutic use; D000818:Animals; D001428:Bacterial Vaccines / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D047630:Depsipeptides; D003888:Desensitization, Immunologic; D005260:Female; D005670:Fusarium; D006801:Humans; D007223:Infant; D007665:Ketotifen / Q000627:therapeutic use; D008297:Male; D008925:Mites / Q000276:immunology; D011446:Prospective Studies; D012130:Respiratory Hypersensitivity / Q000145:classification / Q000188:drug therapy / Q000628:therapy*
D000336:Aerosols; D001428:Bacterial Vaccines; D047630:Depsipeptides; C014001:fusafungin; D007665:Ketotifen
Effet de deux protocoles thérapeutiques dans les formes mineures d'allergies respiratoires.